← Back to The Peptide Bible

About The Peptide Bible

The Peptide Bible is a free, research-backed educational resource on GLP-1 receptor agonists and peptide therapy, published by the Peptide Association. We exist to provide patients, clinicians, and learners with accurate, cited, and accessible information about peptide science — free from commercial bias or vendor influence.

Our Mission

The Peptide Bible was created with a single guiding principle: minimum effective dose, maximum clarity. Peptide therapy is one of the fastest-growing areas of metabolic medicine, but the information landscape is fragmented — scattered across forums, social media, and vendor marketing pages that prioritize sales over science.

We believe patients and providers deserve better. Every section of The Peptide Bible is written to be evidence-based, clearly cited, and accessible to readers at every level — from first-time researchers to practicing clinicians. We do not provide dosing instructions, vendor recommendations, or treatment protocols. We provide the educational foundation so informed conversations with healthcare providers can happen.

Medical Review

All content published in The Peptide Bible is reviewed by licensed healthcare providers through the Peptide Association Medical Advisory Board. This includes board-certified physicians (MD, DO), clinical pharmacologists (PharmD), and specialists in endocrinology, metabolic health, and longevity medicine.

Our medical review process ensures that every claim is supported by current clinical evidence, safety information is presented prominently, and content adheres to the editorial standards expected of health education resources under Google's E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness) framework.

Medical Advisory Board

Our advisory board includes Ian Justl Ellis, MD (Chief Medical Advisor, board-certified emergency medicine physician and founder of Voafit) and additional credentialed clinicians who specialize in GLP-1 medication management, body composition, and evidence-based metabolic health protocols.

Sources & Citations

The Peptide Bible draws exclusively from peer-reviewed research and established clinical sources. Our primary citation sources include:

  • The New England Journal of Medicine (NEJM) — landmark GLP-1 agonist clinical trials (STEP, SURMOUNT, SURPASS)
  • The Lancet — long-term cardiovascular and metabolic outcome data
  • PubMed / MEDLINE — systematic reviews and meta-analyses on peptide compounds
  • ClinicalTrials.gov — ongoing and completed clinical trial registrations
  • FDA.gov — drug approval data, safety communications, and prescribing information

We do not cite forum posts, social media, vendor marketing materials, or unverified anecdotal reports as evidence. When anecdotal perspectives are included for context, they are clearly labeled as such.